Oric Raises $244M, Targets Q1 Dose Update and 1H25 Phase 3 Launch
Oric Pharmaceuticals raised $244 million, extending its cash runway into second-half 2028 to fund Phase 3 trials for rinzimetostat and enozertinib. The company expects Q1 dose-optimization data from 20–25 patients with PSA50/PSA90 metrics and plans to initiate its first prostate cancer Phase 3 study in 1H25.
1. Funding and Runway
Oric raised $244 million mid-2025, extending its cash runway into the second half of 2028. This fully burdened funding covers planned Phase 3 trials for both its PRC2 inhibitor rinzimetostat and EGFR inhibitor enozertinib, contingent on clinical supply agreements for combination partners.
2. Rinzimetostat Phase 3 Prostate Trial
Oric expects Q1 dose-optimization data from 20–25 post-abiraterone or post-androgen receptor inhibitor patients, reporting PSA50 and PSA90 response rates. The company plans to launch its first Phase 3 prostate cancer study in the first half of 2025, combining rinzimetostat with apalutamide or darolutamide.
3. Favorable Safety Profile
Preliminary rinzimetostat data have shown a manageable safety profile with fewer Grade 3/4 gastrointestinal and hematologic adverse events than observed in Pfizer’s PRC2 program. ORIC views this safety advantage as de-risking the allosteric PRC2 mechanism ahead of Phase 3 initiation.
4. Enozertinib CNS Activity and 2H Data Plan
Enozertinib demonstrated 100% CNS response in first-line patients with measurable CNS metastases in EGFR exon 20 and PACC cohorts. The company anticipates second-half data from three 20–25 patient cohorts: first-line EGFR exon 20 monotherapy, EGFR exon 20 plus amivantamab, and first-line PACC monotherapy.